Intersect ENT Announces Appointment of Cynthia L. Lucchese to Board of Directors

  Intersect ENT Announces Appointment of Cynthia L. Lucchese to Board of
  Directors

Business Wire

MENLO PARK, Calif. -- July 11, 2014

Intersect ENT, Inc., a commercial drug-device company committed to improving
the quality of life for patients with ear, nose and throat conditions, today
announced the appointment of Cynthia L. Lucchese to the company’s board of
directors. Ms. Lucchese will serve as chair of the audit committee and as a
member of the nominating and governance committee.

Ms. Lucchese has extensive financial management experience. She most recently
served as senior vice president and chief financial officer of Hillenbrand,
Inc. (NYSE: HI) and as a member of the board of directors of Brightpoint, Inc.
(NASDAQ: CELL), where she served as chair of the audit committee. Previously,
Ms. Lucchese was senior vice president and chief financial officer for
Thoratec Corporation (NASDAQ: THOR) and she held a variety of finance roles,
including vice president and treasurer and chief accounting officer at Guidant
Corporation, now a part of Boston Scientific Corporation. She also spent seven
years with Eli Lilly and Company and several years with the audit division of
Ernst & Young.

“I am thrilled to join the board and to assist the company in its mission of
addressing the clear need for better solutions for ENT physicians and their
patients,” said Ms. Lucchese. “I am excited to be a part of the next chapter
of the organization.”

"Cindy has a wealth of accounting and public company experience combined with
a strong background in the medical device industry," said Lisa Earnhardt,
president and chief executive officer of Intersect ENT. “Cindy brings a
seasoned, global perspective to the board as we seek to expand access to our
technology in the United States and worldwide.”

About Intersect ENT

Intersect ENT, Inc. is a commercial drug-device company committed to improving
the quality of life for patients with ear, nose and throat conditions.
Intersect ENT’s drug-eluting bioabsorbable implant technology enables targeted
and sustained release of therapeutic agents. Intersect ENT’s initial products,
PROPEL and PROPEL mini, are the first and only drug-eluting implants approved
for use in patients with chronic sinusitis. Use of the PROPEL implants is
clinically proven to improve surgical outcomes by maintaining the open
pathways created in surgery and reducing the need for oral steroids and
additional surgical procedures. In addition, Intersect ENT is developing new,
less invasive and more cost-effective drug-eluting bioabsorbable treatment
options for the management of chronic sinusitis in the physician office
setting to provide benefits for patients, physicians and payors.

Contact:

Intersect ENT
Media Contact:
Nicole Osmer, 650-454-0504
nicole@nicoleosmer.com
or
Investor Contact:
Jeri Hilleman, 650-641-2105
ir@intersectent.com
 
Press spacebar to pause and continue. Press esc to stop.